SCHEMBL2528124

SCHEMBL2528124

C=CCN(C(=O)OCc1ccccc1)c1cc(OC)cc(C(=O)O)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.49
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
ALDH1A1 P00352 2/20 0.40
MAPT P10636 1/20 0.40
HPGD P15428 1/20 0.40
HTT P42858 1/20 0.39
GFER P55789 1/20 0.39
HSD17B10 Q99714 1/20 0.39
NR4A2 P43354 1/20 0.39
RAB9A P51151 3/20 0.39
MRGPRX4 Q96LA9 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
TP53 P04637 1/20 0.39
PKM P14618 1/20 0.39
NFKB1 P19838 1/20 0.39
NFKB2 Q00653 1/20 0.39
RELA Q04206 1/20 0.39
RXFP1 Q9HBX9 1/20 0.39
PTGES O14684 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2526880 0.92 TSHR (0.47) TSHRKMT2AALDH1A1MAPTHPGD
SCHEMBL3184630 0.89 KMT2A (0.41) TSHRMEN1KMT2AALDH1A1MAPT
SCHEMBL2532574 0.88 MEN1 (0.45) TSHRMEN1KMT2AALDH1A1MAPT
SCHEMBL2526914 0.87 TSHR (0.41) TSHRMEN1KMT2AALDH1A1MAPT
SCHEMBL2526958 0.87 ALDH1A1 (0.41) TSHRMEN1KMT2AALDH1A1MAPT
SCHEMBL2530897 0.85 ALDH1A1 (0.43) TSHRMEN1KMT2AALDH1A1MAPT
SCHEMBL4874179 0.84 ALDH1A1 (0.42) TSHRMEN1KMT2AALDH1A1MAPT
SCHEMBL4872653 0.82 ALDH1A1 (0.40) TSHRMEN1KMT2AALDH1A1MAPT
SCHEMBL4877059 0.82 MEN1 (0.39) TSHRMEN1KMT2AALDH1A1MAPT
SCHEMBL3185237 0.81 KMT2A (0.41) TSHRMEN1KMT2AALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8039455-B2 Macrocyclic compounds useful as BACE inhibitors NOVARTIS AG (CH) 2011-10-18 US disclosed
US-20090029960-A1 MACROCYCLIC COMPOUNDS USEFUL AS BASE INHIBITORS NOVARTIS AG (CH) 2009-01-29 US disclosed
EP-1968954-A1 MACROCYCLIC COMPOUNDS USEFUL AS BACE INHIBITORS Novartis AG (CH) 2008-09-17 EP disclosed
WO-2007077004-A1 MACROCYCLIC COMPOUNDS USEFUL AS BACE INHIBITORS NOVARTIS AG (CH) 2007-07-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090029960-A1 MACROCYCLIC COMPOUNDS USEFUL AS BASE INHIBITORS SLC10A2, SLC10A1, ASAH2 TSHR 3177/4885MEN1 26/4885KMT2A 2735/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.